MedPath

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Brain Stem Glioma

Phase 1
Completed
Conditions
Brain Tumors
Central Nervous System Tumors
Interventions
Registration Number
NCT00003625
Lead Sponsor
Children's Oncology Group
Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one chemotherapy drug with radiation therapy may kill more tumor cells.

PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy plus radiation therapy in treating patients with newly diagnosed brain stem glioma.

Detailed Description

OBJECTIVES: I. Determine the maximum tolerated dose and dose limiting toxicity of vincristine given as an IV push dose in combination with continuous infusion cyclosporine and oral etoposide concurrent with and prior to radiotherapy in children with newly diagnosed primary intrinsic brain stem glioma. II. Determine the incidence and severity of other toxicities of vincristine in this regimen in these patients. III. Determine a safe and tolerable dose of vincristine under these conditions to be used in phase II studies. IV. Seek preliminary evidence of antitumor activity in this setting in these patients.

OUTLINE: This is dose escalation study of vincristine. Patients receive radiotherapy daily for 6 weeks with concurrent induction chemotherapy. Induction chemotherapy consists of vincristine IV push weekly for 6 weeks, oral etoposide daily on days 1-21 and 29-49 and cyclosporine IV over 2 hours prior to vincristine followed by a continuous 36 hour infusion. Cohorts of 3-6 patients receive escalating doses of vincristine. If dose limiting toxicity (DLT) occurs in 2 or more of 3-6 patients, the maximum tolerated dose (MTD) has been exceeded and the preceding dose is declared the MTD. Maintenance therapy consists of 6 monthly courses of cyclosporine IV over 36 hours beginning on day 1, vincristine IV push on day 1, and oral etoposide daily for days 1-21. Patients are followed every 6 months for 4 years and then annually thereafter.

PROJECTED ACCRUAL: At least 6 patients will be accrued into this study at a rate of 12 patients per year.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
7
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Stratum 1radiation therapyConcomitant irradiation and vincristine sulfate in esc dose beginning with 0.8 mg/m2, etoposide and Cyclosporine A given over 6 weeks, then monthly maint courses over 6 mths, with no clinical and radiologic progression. Stable disease indicates continuation of therapy. Clinical deterioration within 4 months of completion of radiation therapy must be confirmed to be PD by imaging. Clinical progression even in the absence of imaging changes will be accepted as reflecting disease progression. Steroids dexamethasone (Decadron) given as clinically indicated and tapered as tolerated. Steroids may decrease capillary permeability to chemotherapeutic agents and antagonise the effect of cyclosporin A. Also contributes to the syndrome of seizures and white matter changes seen with cyclosporine in the post BMT period. If steroid use is required, the recommended schedule of Decadron dosing during the 6 week induction course is 8 mg/m2 divided q 6-8 hours.
Stratum 1etoposideConcomitant irradiation and vincristine sulfate in esc dose beginning with 0.8 mg/m2, etoposide and Cyclosporine A given over 6 weeks, then monthly maint courses over 6 mths, with no clinical and radiologic progression. Stable disease indicates continuation of therapy. Clinical deterioration within 4 months of completion of radiation therapy must be confirmed to be PD by imaging. Clinical progression even in the absence of imaging changes will be accepted as reflecting disease progression. Steroids dexamethasone (Decadron) given as clinically indicated and tapered as tolerated. Steroids may decrease capillary permeability to chemotherapeutic agents and antagonise the effect of cyclosporin A. Also contributes to the syndrome of seizures and white matter changes seen with cyclosporine in the post BMT period. If steroid use is required, the recommended schedule of Decadron dosing during the 6 week induction course is 8 mg/m2 divided q 6-8 hours.
Stratum 1vincristine sulfateConcomitant irradiation and vincristine sulfate in esc dose beginning with 0.8 mg/m2, etoposide and Cyclosporine A given over 6 weeks, then monthly maint courses over 6 mths, with no clinical and radiologic progression. Stable disease indicates continuation of therapy. Clinical deterioration within 4 months of completion of radiation therapy must be confirmed to be PD by imaging. Clinical progression even in the absence of imaging changes will be accepted as reflecting disease progression. Steroids dexamethasone (Decadron) given as clinically indicated and tapered as tolerated. Steroids may decrease capillary permeability to chemotherapeutic agents and antagonise the effect of cyclosporin A. Also contributes to the syndrome of seizures and white matter changes seen with cyclosporine in the post BMT period. If steroid use is required, the recommended schedule of Decadron dosing during the 6 week induction course is 8 mg/m2 divided q 6-8 hours.
Stratum 1cyclosporineConcomitant irradiation and vincristine sulfate in esc dose beginning with 0.8 mg/m2, etoposide and Cyclosporine A given over 6 weeks, then monthly maint courses over 6 mths, with no clinical and radiologic progression. Stable disease indicates continuation of therapy. Clinical deterioration within 4 months of completion of radiation therapy must be confirmed to be PD by imaging. Clinical progression even in the absence of imaging changes will be accepted as reflecting disease progression. Steroids dexamethasone (Decadron) given as clinically indicated and tapered as tolerated. Steroids may decrease capillary permeability to chemotherapeutic agents and antagonise the effect of cyclosporin A. Also contributes to the syndrome of seizures and white matter changes seen with cyclosporine in the post BMT period. If steroid use is required, the recommended schedule of Decadron dosing during the 6 week induction course is 8 mg/m2 divided q 6-8 hours.
Primary Outcome Measures
NameTimeMethod
Event Free Survival
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (74)

Baptist Hospital of Miami

🇺🇸

Miami, Florida, United States

Arizona Cancer Center

🇺🇸

Tucson, Arizona, United States

Lucile Packard Children's Hospital at Stanford

🇺🇸

Palo Alto, California, United States

University of California San Diego Cancer Center

🇺🇸

La Jolla, California, United States

Kaiser Permanente Medical Center - Santa Clara

🇺🇸

Santa Clara, California, United States

Nemours Children's Clinic

🇺🇸

Jacksonville, Florida, United States

Sylvester Cancer Center, University of Miami

🇺🇸

Miami, Florida, United States

St. Mary's Hospital

🇺🇸

West Palm Beach, Florida, United States

Emory University Hospital - Atlanta

🇺🇸

Atlanta, Georgia, United States

Rush-Presbyterian-St. Luke's Medical Center

🇺🇸

Chicago, Illinois, United States

Children's Memorial Hospital, Chicago

🇺🇸

Chicago, Illinois, United States

Christ Hospital

🇺🇸

Oak Lawn, Illinois, United States

Saint Jude Midwest Affiliate

🇺🇸

Peoria, Illinois, United States

Eastern Maine Medical Center

🇺🇸

Bangor, Maine, United States

Maine Children's Cancer Program

🇺🇸

Portland, Maine, United States

Johns Hopkins Oncology Center

🇺🇸

Baltimore, Maryland, United States

Floating Hospital for Children

🇺🇸

Boston, Massachusetts, United States

Massachusetts General Hospital Cancer Center

🇺🇸

Boston, Massachusetts, United States

Dana-Farber Cancer Institute

🇺🇸

Boston, Massachusetts, United States

Hurley Medical Center

🇺🇸

Flint, Michigan, United States

Keesler Medical Center - Keesler AFB

🇺🇸

Keesler AFB, Mississippi, United States

Cardinal Glennon Children's Hospital

🇺🇸

Saint Louis, Missouri, United States

University of Missouri-Columbia Hospital and Clinics

🇺🇸

Columbia, Missouri, United States

Norris Cotton Cancer Center

🇺🇸

Lebanon, New Hampshire, United States

Hackensack University Medical Center

🇺🇸

Hackensack, New Jersey, United States

University of New Mexico School of Medicine

🇺🇸

Albuquerque, New Mexico, United States

State University of New York Health Sciences Center - Stony Brook

🇺🇸

Stony Brook, New York, United States

Roswell Park Cancer Institute

🇺🇸

Buffalo, New York, United States

State University of New York - Upstate Medical University

🇺🇸

Syracuse, New York, United States

Natalie Warren Bryant Cancer Center

🇺🇸

Tulsa, Oklahoma, United States

James H. Quillen College of Medicine

🇺🇸

Johnson City, Tennessee, United States

Saint Jude Children's Research Hospital

🇺🇸

Memphis, Tennessee, United States

Medical City Dallas Hospital

🇺🇸

Dallas, Texas, United States

Simmons Cancer Center - Dallas

🇺🇸

Dallas, Texas, United States

Cook Children's Medical Center - Fort Worth

🇺🇸

Fort Worth, Texas, United States

University of Texas Medical Branch

🇺🇸

Galveston, Texas, United States

Baylor College of Medicine

🇺🇸

Houston, Texas, United States

San Antonio Military Pediatric Cancer and Blood Disorders Center

🇺🇸

Lackland Air Force Base, Texas, United States

Scott and White Clinic

🇺🇸

Temple, Texas, United States

Vermont Cancer Center

🇺🇸

Burlington, Vermont, United States

Inova Fairfax Hospital

🇺🇸

Falls Church, Virginia, United States

Carilion Roanoke Memorial Hospital

🇺🇸

Roanoke, Virginia, United States

West Virginia University Medical School, Charleston Division

🇺🇸

Charleston, West Virginia, United States

Madigan Army Medical Center

🇺🇸

Tacoma, Washington, United States

St. Vincent Hospital

🇺🇸

Green Bay, Wisconsin, United States

West Virginia University Hospitals

🇺🇸

Morgantown, West Virginia, United States

Alberta Children's Hospital

🇨🇦

Calgary, Alberta, Canada

Hospital for Sick Children

🇨🇦

Toronto, Ontario, Canada

Children's Hospital of Eastern Ontario

🇨🇦

Ottawa, Ontario, Canada

Centre Hospitalier de L'Universite Laval

🇨🇦

Sainte Foy, Quebec, Canada

Montreal Children's Hospital

🇨🇦

Montreal, Quebec, Canada

Hopital Sainte Justine

🇨🇦

Montreal, Quebec, Canada

Academisch Ziekenhuis Groningen

🇳🇱

Groningen, Netherlands

Clinique de Pediatrie

🇨🇭

Geneva, Switzerland

San Jorge Childrens Hospital

🇵🇷

Santurce, Puerto Rico

Kaiser Permanente-Southern California Permanente Medical Group

🇺🇸

San Diego, California, United States

Naval Medical Center - San Diego

🇺🇸

San Diego, California, United States

Duke Comprehensive Cancer Center

🇺🇸

Durham, North Carolina, United States

University of Texas Health Science Center at San Antonio

🇺🇸

San Antonio, Texas, United States

Tripler Army Medical Center

🇺🇸

Honolulu, Hawaii, United States

University of Mississippi Medical Center

🇺🇸

Jackson, Mississippi, United States

Via Christi Regional Medical Center-Saint Francis Campus

🇺🇸

Wichita, Kansas, United States

Children's Hospital of Michigan

🇺🇸

Detroit, Michigan, United States

Oklahoma Memorial Hospital

🇺🇸

Oklahoma City, Oklahoma, United States

University of Alabama Comprehensive Cancer Center

🇺🇸

Birmingham, Alabama, United States

St. John's Hospital and Medical Center

🇺🇸

Detroit, Michigan, United States

Washington University School of Medicine

🇺🇸

Saint Louis, Missouri, United States

Midwest Children's Cancer Center

🇺🇸

Milwaukee, Wisconsin, United States

Sutter Cancer Center

🇺🇸

Sacramento, California, United States

Walt Disney Memorial Cancer Institute

🇺🇸

Orlando, Florida, United States

Tulane University School of Medicine

🇺🇸

New Orleans, Louisiana, United States

Medical University of South Carolina

🇺🇸

Charleston, South Carolina, United States

University of Arkansas for Medical Sciences

🇺🇸

Little Rock, Arkansas, United States

University of Kansas Medical Center

🇺🇸

Kansas City, Kansas, United States

© Copyright 2025. All Rights Reserved by MedPath